Ultragenyx Pharmaceutical Inc.

385 articles with Ultragenyx Pharmaceutical Inc.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023

  3/21/2023

  Ultragenyx Pharmaceutical Inc. today reported the grant of non-qualified stock options to purchase an aggregate of 7,130 shares of common stock of the company and 5,885 restricted stock units of the company’s common stock to ten newly hired non-executive officers of the company.

• Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

  3/14/2023

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role.

• Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference

  2/28/2023

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in an Orphan Neuro Panel at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET.

• Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

  2/16/2023

  Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter and full year ended December 31, 2022 and reaffirmed its financial guidance for 2023.

• Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

  2/9/2023

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will host a conference call on Thursday, February 16, 2023, at 5:00 p.m. ET to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2022.

• Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

  1/6/2023

  Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2022 revenue results, cash and investments at year end 2022, and provided 2023 guidance on select key financial metrics including net cash used in operations.

• Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Ultragenyx Pharmaceutical Inc. today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET.

• 

  Voyager's Al Sandrock, Alnylam's Yvonne Greenstreet and More Share Their Predictions for 2023

  12/23/2022

  BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 21, 2022

  12/21/2022

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 29,950 shares of common stock of the company and 17,505 restricted stock units of the company’s common stock to three newly hired non-executive officers of the company.

• Ultragenyx to Present at Piper Sandler Healthcare Conference - November 22, 2022

  11/22/2022

  Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Piper Sandler Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:00 AM ET in New York.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - November 18, 2022

  11/18/2022

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 5,380 shares of common stock of the company and 5,000 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company.

• Ultragenyx Announces Departure of Chief Financial Officer

  11/10/2022

  Ultragenyx Pharmaceutical Inc. announced that Mardi Dier, Chief Financial Officer and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC.

• Ultragenyx to Present at Upcoming Healthcare Conferences - November 09, 2022

  11/9/2022

  Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences.

• Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

  11/2/2022

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2022 and provided a corporate update for the year.

• Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

  10/27/2022

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will host a conference call on Wednesday, November 2, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2022.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022

  10/4/2022

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 13,000 shares of common stock of the company and 6,500 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company.

• Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

  9/9/2022

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), and Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo”), today announced that additional data from Mereo’s Phase 2b ASTEROID study related to setrusumab (UX143) and information on the Phase 2/3 Orbit study will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting.

• Ultragenyx to Participate at Citi BioPharma Conference

  9/1/2022

  Ultragenyx Pharmaceutical Inc. announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 17, 2022

  8/17/2022

  Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, reported the grant of non-qualified stock options to purchase an aggregate of 19,020 shares of common stock of the company and 12,910 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2022

  8/3/2022

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 27,500 shares of common stock of the company and 14,500 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.